{"id":409062,"date":"2019-08-27T00:00:00","date_gmt":"2019-08-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2019-biopharma-psoriasis-access-and-reimbursement-us-2019\/"},"modified":"2026-03-31T10:46:27","modified_gmt":"2026-03-31T10:46:27","slug":"acreim0017-2019-biopharma-psoriasis-access-and-reimbursement-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2019-biopharma-psoriasis-access-and-reimbursement-us-2019\/","title":{"rendered":"Psoriasis | Access and Reimbursement | US | 2019"},"content":{"rendered":"<p>MARKET OUTLOOK<\/p>\n<p>In the past decade, tumor necrosis factor-alpha (TNF-\u03b1) inhibitors, including AbbVie\u2019s Humira and Amgen\u2019s Enbrel, and Janssen\u2019s interleukin IL-12\/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals of novel psoriasis agents is altering the market landscape. Celgene\u2019s oral agent Otezla has been successfully carving out a space in biologics-naive patients. More-effective biologics\u2014the IL-17 inhibitors Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz\u2014are threatening the first-line dominance of the TNF-\u03b1 inhibitors, and Janssen\u2019s IL-23 inhibitor Tremfya is likely to follow. With the recent entry of biosimilars and another IL-23 inhibitor, an IL-17 A\/F dual inhibitor, and an oral TYK2 inhibitor in late-phase development, marketers of psoriasis therapies must learn how to overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the current patient-share leaders among psoriasis biologics\/Otezla, and which psoriasis agents do physicians and payers perceive to perform best on specific clinical and market access factors?<\/li>\n<li>How do payers cover biosimilar versions of infliximab (Pfizer\u2019s Inflectra, Merck\u2019s Renflexis), and what are physicians\u2019 expected prescribing behaviors toward biosimilars?<\/li>\n<li>What are physicians\u2019 perceptions of emerging biologics, such as Skyrizi, mirikizumab, bimekizumab, and BMS-986165, and how do payers anticipate covering these agents?<\/li>\n<li>What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-409062","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409062\/revisions"}],"predecessor-version":[{"id":409189,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409062\/revisions\/409189"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=409062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}